Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 8/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | GHSR | Q92847 | 1/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 6/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 6/20 | 0.43 |
| ▸ | ADRB3 | P13945 | 6/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6074962 | 0.91 | ADRB2 (0.49) | ARPOLBTDP1GHSRADRB2 | |
| SCHEMBL6075083 | 0.88 | GHSR (0.50) | ARGHSR | |
| SCHEMBL6074935 | 0.85 | ADRB3 (0.55) | ADRB2ADRB1ADRB3 | |
| SCHEMBL6982753 | 0.80 | ADRB3 (0.42) | ARPOLBADRB2ADRB1ADRB3 | |
| SCHEMBL6074963 | 0.79 | GAA (0.45) | POLBADRB3LMNASMN1; SMN2 | |
| SCHEMBL6074807 | 0.78 | POLB (0.45) | POLBADRB3SMN1; SMN2CACNA1B | |
| SCHEMBL6074347 | 0.76 | ADRB3 (0.52) | ADRB2ADRB1ADRB3LMNASMN1; SMN2 | |
| SCHEMBL6074513 | 0.76 | ADRB1 (0.54) | TDP1GHSRADRB2ADRB1ADRB3 | |
| SCHEMBL6983313 | 0.74 | ALDH1A1 (0.42) | POLBADRB2ADRB1ADRB3PTPN2 | |
| SCHEMBL6075016 | 0.74 | ADRB3 (0.44) | POLBADRB2ADRB1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7022716-B2 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | WYETH (US) | 2006-04-04 | — | — | US | disclosed |
| US-20030144326-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | WYETH | 2003-07-31 | — | — | US | disclosed |
| US-6525202-B2 | E.g., substituted (4-amino-5-hydroxyphenyl)-oxy-)piperidinyl thiazolidin-2,4-dione; antidiabetic agents; atherosclerosis, gastrointestinal, metabolic disorders, glaucoma, neurogenetic inflammation, ocular hypertension and frequent urination | WYETH | 2003-02-25 | — | — | US | disclosed |
| US-20020028835-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | WYETH | 2002-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144326-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | AR 285/4885POLB 1964/4885TDP1 1110/4885 |
| US-20020028835-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | AR 285/4885POLB 1964/4885TDP1 1110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.